Oncolys BioPharma Inc. announced that the investigator-initiated Phase 2 clinical trial agreement with Weill Cornell Medicine, for Immunotherapy refractory Esophagogastric adenocarcinoma has been executed. This clinical trial is led by Dr. Manish Shah, the Bartlett Family Professor in Gastrointestinal Oncology in the Division of Hematology and Medical Oncology, Department of Medicine, Member of the Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, and Chief of the Solid Tumor Oncology Service and Co-Director of the Center for Advanced Digestive Care, NewYork-Presbyterian/Weill Cornell Medical Center. This agreement establishes a collaborative development framework for Suratadenoturev (OBP-301) and Pembrolizaumb among three parties: Oncolys, Weill Cornell Medicine and Merck & Co.

Inc.'s ("Merck"). Costs of this study will be shared between Oncolys and Merck. A prior Phase 2 study in 3rd line esophagogastric adenOCarcinoma (GEA) patients combining suratadenoturev (obP-301) and an anti-PD-1 therapy previously led by Dr. Manishah and demonstrated that the combination is well tolerated and has encouraging activity in GEA, with durable responses and demonstration of activity in immunotherapy refractory disease.

This new phase II multi-center clinical study of suratadenoturev with an anti-PD-1 Therapy in an immunotherapy (IO) refractory advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma patients, targets an important unmet need in drug development. The impact of Immune check point inhibitors (ICI) therapy on survival for upper gastrointestinal cancers has been transformative, with a majority of patients receiving ICI therapy with chemotherapy in the first line treatment setting. However, there are no therapies involving ICI therapy in patients who are refractory to immunotherapy, which is an important unmet medical need to develop new targeted therapies for gastroesophageal cancer in an immunotherapy refractory population.

Oncolys expects that the combination of suratadenotureV (OBP-301) with pembrolizumab will lead to clinical efficacy and ultimately improved patient survival. Oncolys aims to contribute to the development of cancer therapies that helps the medical field by continue to conduct research and development on the combination of Telomelysin based on the concept of "cure cancer without. surgery," and other treatment.